STAT+: Grail CEO steps down after trial setback
Chronological Source Flow
Back
AI Fusion Summary
Grail CEO resigns following trial setback. Cancer researchers find a notorious oncogene sometimes exposed on tumor cell surfaces, suggesting a new immunotherapy target. Trump maintains messaging advantage on drug pricing. Biotech social circles feel awkward again due to the return of an Epstein-linked investor.
Comments